Open Access

Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats

  • Authors:
    • Xiaoxia Song
    • Wencheng Yu
    • Fang Guo
  • View Affiliations

  • Published online on: June 29, 2018     https://doi.org/10.3892/etm.2018.6378
  • Pages: 1800-1806
  • Copyright: © Song et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the effect of pirfenidone on bleomycin‑induced lung fibrosis in rats, in order to elucidate the underlying mechanism of periostin‑induced fibrosis. The lung fibrosis model was constructed using a single intratracheal instillation of bleomycin in rats. The normal rats without bleomycin administration were used as controls (n=24). Bleomycin‑treated rats were randomized into the model (M) or pirfenidone (P) group (n=24 per group). Rats were sacrificed on days 7, 14 and 28 following treatment. Hematoxylin‑eosin and Masson's trichrome staining were performed to analyze pulmonary alveolitis and fibrosis. Periostin location was detected by immunohistochemistry. Hydroxyproline content, and expression of periostin and transforming growth factor (TGF)‑β1 were detected by ELISA, reverse transcription‑quantitative polymerase chain reaction or western blotting. Correlation of periostin expression with hydroxyproline and TGF‑β1 content was also analyzed. Histological findings demonstrated that pirfenidone significantly inhibited bleomycin‑induced lung fibrosis and reduced the hydroxyproline content on day 14 and day 28 compared with the model group (P<0.05 or P<0.01). Furthermore, the bleomycin‑induced increased protein expression of periostin and TGF‑β1 was also significantly suppressed by pirfenidone on days 14 (P<0.01) and 28 (data not shown). Furthermore, periostin expression was significantly correlated with hydroxyproline and TGF‑β1 content, and fibrosis score (P<0.001). The present findings suggest that the antifibrotic effect of pirfenidone may be achieved by suppression of periostin and TGF‑β1 expression in rat pulmonary fibrogenesis.
View Figures
View References

Related Articles

Journal Cover

September-2018
Volume 16 Issue 3

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song X, Yu W and Guo F: Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats. Exp Ther Med 16: 1800-1806, 2018
APA
Song, X., Yu, W., & Guo, F. (2018). Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats. Experimental and Therapeutic Medicine, 16, 1800-1806. https://doi.org/10.3892/etm.2018.6378
MLA
Song, X., Yu, W., Guo, F."Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats". Experimental and Therapeutic Medicine 16.3 (2018): 1800-1806.
Chicago
Song, X., Yu, W., Guo, F."Pirfenidone suppresses bleomycin‑induced pulmonary fibrosis and periostin expression in rats". Experimental and Therapeutic Medicine 16, no. 3 (2018): 1800-1806. https://doi.org/10.3892/etm.2018.6378